Andrea Stefekova1,2, Pavlina Capkova1,2, Zuzana Capkova1,2, Vaclava Curtisova1, Josef Srovnal3,4, Enkhjargalan Mracka1,2, Eva Klaskova2,4, Martin Prochazka1,2. 1. Department of Medical Genetics, University Hospital Olomouc, Czech Republic. 2. Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. 3. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic. 4. Department of Pediatrics, University Hospital Olomouc, Czech Republic.
Abstract
AIMS: The aim of this retrospective study was to determine the detection rate of the pathogenic copy number variants (CNVs) in a cohort of 33 foetuses - 32 with CHD (congenital heart defects) and 1 with kidney defect, after exclusion of common aneuploidies (trisomy 13, 18, 21, and monosomy X) by karyotyping, Multiplex ligation - dependent probe amplification (MLPA) and chromosomal microarray analysis (CMA). We also assess the effectivity of MLPA as a method of the first tier for quick and inexpensive detection of mutations, causing congenital malformations in foetuses. METHODS: MLPA with probe mixes P070, P036 - Telomere 3 and 5, P245 - microdeletions, P250 - DiGeorge syndrome, and P311 - CHD (Congenital heart defects) was performed in 33 samples of amniotic fluid and chorionic villi. CMA was performed in 10 relevant cases. RESULTS: Pathogenic CNVs were found in 5 samples: microdeletions in region 22q11.2 (≈2 Mb) in two foetuses, one distal microdeletion of the 22q11.2 region containing genes LZTR1, CRKL, AIFM3 and SNAP29 (≈416 kb) in the foetus with bilateral renal agenesis, 8p23.1 (3.8 Mb) microdeletion syndrome and microdeletion in area 9q34.3 (1.7 Mb, Kleefstra syndrome). MLPA as an initial screening method revealed unambiguously pathogenic CNVs in 15.2 % of samples. CONCLUSION: Our study suggests that MLPA and CMA are a reliable and high-resolution technology and should be used as the first-tier test for prenatal diagnosis of congenital heart disease. Determination of the cause of the abnormality is crucial for genetic counselling and further management of the pregnancy.
AIMS: The aim of this retrospective study was to determine the detection rate of the pathogenic copy number variants (CNVs) in a cohort of 33 foetuses - 32 with CHD (congenital heart defects) and 1 with kidney defect, after exclusion of common aneuploidies (trisomy 13, 18, 21, and monosomy X) by karyotyping, Multiplex ligation - dependent probe amplification (MLPA) and chromosomal microarray analysis (CMA). We also assess the effectivity of MLPA as a method of the first tier for quick and inexpensive detection of mutations, causing congenital malformations in foetuses. METHODS: MLPA with probe mixes P070, P036 - Telomere 3 and 5, P245 - microdeletions, P250 - DiGeorge syndrome, and P311 - CHD (Congenital heart defects) was performed in 33 samples of amniotic fluid and chorionic villi. CMA was performed in 10 relevant cases. RESULTS: Pathogenic CNVs were found in 5 samples: microdeletions in region 22q11.2 (≈2 Mb) in two foetuses, one distal microdeletion of the 22q11.2 region containing genes LZTR1, CRKL, AIFM3 and SNAP29 (≈416 kb) in the foetus with bilateral renal agenesis, 8p23.1 (3.8 Mb) microdeletion syndrome and microdeletion in area 9q34.3 (1.7 Mb, Kleefstra syndrome). MLPA as an initial screening method revealed unambiguously pathogenic CNVs in 15.2 % of samples. CONCLUSION: Our study suggests that MLPA and CMA are a reliable and high-resolution technology and should be used as the first-tier test for prenatal diagnosis of congenital heart disease. Determination of the cause of the abnormality is crucial for genetic counselling and further management of the pregnancy.
Authors: L Faivre; N Morichon-Delvallez; G Viot; F Narcy; S Loison; L Mandelbrot; M C Aubry; V Raclin; P Edery; A Munnich; M Vekemans Journal: Prenat Diagn Date: 1998-10 Impact factor: 3.050
Authors: Richard Paylor; Beate Glaser; Annalisa Mupo; Paris Ataliotis; Corinne Spencer; Angela Sobotka; Chelsey Sparks; Chul-Hee Choi; John Oghalai; Sarah Curran; Kieran C Murphy; Stephen Monks; Nigel Williams; Michael C O'Donovan; Michael J Owen; Peter J Scambler; Elizabeth Lindsay Journal: Proc Natl Acad Sci U S A Date: 2006-05-09 Impact factor: 11.205
Authors: Rejane A C Monteiro; Mariana L de Freitas; Gabrielle S Vianna; Valdirene T de Oliveira; Rafaella X Pietra; Luana C A Ferreira; Patrícia P O Rocha; Michele da S Gonçalves; Giovana da C César; Joziele de S Lima; Paula F V Medeiros; Juliana F Mazzeu; Fernanda S Jehee Journal: Mol Syndromol Date: 2017-06-14
Authors: Simone Sanna-Cherchi; Pietro Ravani; Valentina Corbani; Stefano Parodi; Riccardo Haupt; Giorgio Piaggio; Maria L Degli Innocenti; Danio Somenzi; Antonella Trivelli; Gianluca Caridi; Claudia Izzi; Francesco Scolari; Girolamo Mattioli; Landino Allegri; Gian Marco Ghiggeri Journal: Kidney Int Date: 2009-06-17 Impact factor: 10.612
Authors: Marta Unolt; Molka Kammoun; Beata Nowakowska; Gail E Graham; T Blaine Crowley; Matthew S Hestand; Wolfram Demaerel; Maciej Geremek; Beverly S Emanuel; Elaine H Zackai; Joris R Vermeesch; Donna McDonald-McGinn Journal: Genet Med Date: 2019-09-02 Impact factor: 8.822